The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation
Authors:
Open Access
- 19 November 2019
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (4) , 661-669
Abstract
Purpose: To investigate if patients receiving neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) had an increased risk of thromboembolic events (TEE) and to evaluate when these events occur on a timeline starting from 6 months pre-cystectomy, during NAC-administration and 60 months post-cystectomy. Methods: Two hundred and fifty five patients undergoing radical cystectomy during 2009–2014 at three Swedish cystectomy centers (Umeå, Linköping and Sundsvall) were in-detail reviewed retrospectively, using individual medical records. One hundred and twenty nine patients were ineligible for analysis. NAC patients (n = 67) were compared to NAC-naïve NAC-eligible patients (n = 59). The occurrence of TEE was divided into different periods pre-cystectomy and post-cystectomy. Statistical analyses included Chi-squared and logistical regression tests. Results: Significant associations were found between receiving NAC and acquiring a TEE during NAC therapy pre-cystectomy. All but one pre-cystectomy event was venous and all but one of the patients received NAC. 31% (14/45) of TEEs occurred pre-cystectomy. The incidence of TEEs pre-cystectomy in NAC-naive NAC-eligible patients was only 10% (2/20), whereas the incidence of TEEs in NAC patients occurred pre-cystectomy in 48% (12/25) and 11/12 incidents were detected during NAC therapy—this including 7/11 (64%) incidents affecting veins in anatomical conjunction with the placement of central venous access for chemotherapy administration. Conclusions: There is a significantly increased risk for TEE pre-cystectomy during chemotherapy administration in MIBC patients receiving NAC, compared to the risk in NAC-naïve NAC-eligible MIBC patients. In 64% of the pre-RC TEEs in NAC patients, there was a clinical connection to placement of central venous access.Keywords
Funding Information
- Västerbotten Läns Landsting (Bas-ALF/VLL RV-848051)
- The Cancer Research Foundation in Norrland, Umeå, Sweden (CFF LP 13-2000)
This publication has 21 references indexed in Scilit:
- No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based studyWorld Journal of Urology, 2019
- A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapySpringerPlus, 2016
- Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011Urologic Oncology: Seminars and Original Investigations, 2016
- Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a population‐based studyBJU International, 2016
- The mechanisms of cancer-associated thrombosisThrombosis Research, 2015
- Central venous catheter–related thrombosisHematology-American Society Hematology Education Program, 2014
- Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomyUrologic Oncology: Seminars and Original Investigations, 2014
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder CancerEuropean Urology, 2012
- Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studiesThrombosis Research, 2009